Get the Stockscreener App
3.6205
3.08%
-0.1095
Curevac N V stock is traded at $3.6205, with a volume of 523.64K.
It is down -3.08% in the last 24 hours and down -22.76% over the past month.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$3.73
Open:
$3.71
24h Volume:
523.64K
Relative Volume:
0.68
Market Cap:
$836.78M
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
6.6019
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-4.62%
1M Performance:
-22.76%
6M Performance:
+8.89%
1Y Performance:
+3.58%
1-Day Range:
$3.58
$3.755
1-Week Range:
$3.49
$3.95
52-Week Range:
$2.215
$5.28
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
3.62 | 836.78M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.58 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.35 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
Individual investors among CureVac N.V.'s (NASDAQ:CVAC) largest stockholders and were hit after last week's 6.1% price drop - Simply Wall St
CureVac (NASDAQ:CVAC) Trading Down 5.8%Here's Why - MarketBeat
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia - MSN
CureVac NV (FRA:5CV) Altman Z-Score : 3.43 (As of Feb. 01, 2025) - GuruFocus.com
CureVac NV (FRA:5CV) Momentum Rank : 7 (As of Feb. 01, 2025) - GuruFocus.com
CureVac (NASDAQ:CVAC) Shares Sold by Ballentine Partners LLC - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update - ACCESS Newswire
Brokers Offer Predictions for CureVac FY2025 Earnings - Defense World
22,946 Shares in CureVac (NASDAQ:CVAC) Bought by Barclays PLC - Defense World
FY2025 EPS Estimates for CureVac Raised by Leerink Partnrs - MarketBeat
Companies Like CureVac (NASDAQ:CVAC) Are In A Position To Invest In Growth - Yahoo Finance
CureVac (NASDAQ:CVAC) Stock Price Down 3.7%What's Next? - MarketBeat
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Up 4.7%Should You Buy? - MarketBeat
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing - Benzinga
Jane Street Group LLC Has $235,000 Stock Position in CureVac (NASDAQ:CVAC) - Defense World
Geode Capital Management LLC Lowers Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac NV (FRA:5CV) 50-Day SMA : €2.91 (As of Jan. 11, 2025) - GuruFocus.com
CVAC (CureVac NV) 14-Day RSI : 68.17 (As of Jan. 10, 2025) - GuruFocus.com
CureVac (NASDAQ:CVAC) Trading 5.7% HigherHere's What Happened - MarketBeat
Why CureVac (CVAC) Shares Are Volatile - Benzinga
CureVac: Latest GBM Data Bodes Well For Next Program Check Point (NASDAQ:CVAC) - Seeking Alpha
Why CureVac (CVAC) Stock Is Moving - Benzinga
CureVac (NASDAQ:CVAC) Shares Gap DownHere's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Gap UpHere's Why - MarketBeat
Why CureVac (CVAC) Stock Is Rising - Benzinga
Vaccine stocks gain amid uptick in flu, COVID-19, RSV (CVAC:NASDAQ) - Seeking Alpha
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25% - Simply Wall St
Short Interest in CureVac (NASDAQ:CVAC) Declines By 6.4% - MarketBeat
CureVac (NASDAQ:CVAC) Trading Up 3.6% – Still a Buy? - Defense World
CureVac (NASDAQ:CVAC) Stock Quotes, Forecast and News Summary - Benzinga
CureVac (NASDAQ:CVAC) Stock Price Up 3.6%Here's What Happened - MarketBeat
Discover 3 US Penny Stocks With Market Caps Over $200M - Simply Wall St
CureVac (NASDAQ:CVAC) Trading Up 4.7%What's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 5.5%What's Next? - MarketBeat
CureVac's SWOT analysis: mRNA pioneer's stock faces oncology pipeline hurdles - Investing.com
2 Small-Cap Stocks Set to Shine in a Bull Market - Benzinga
CUREVAC : Licensing deal boosts bank account - Marketscreener.com
Point72 Asset Management L.P. Sells 1,642,723 Shares of CureVac (NASDAQ:CVAC) - MarketBeat
CUREVAC : Positive one-off overshadows pipeline dryness - Marketscreener.com
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
CureVac NV (XTER:5CV) 50-Day SMA : €2.62 (As of Dec. 05, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 5-Day RSI : 64.31 (As of Dec. 05, 2024) - GuruFocus.com
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal phase in oncology push - Investing.com
CureVac NV (LTS:0A9E) EBITDA per Share : $0.84 (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CureVac NV (WBO:CVAC) Enterprise Value : €94.9 Mil (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Altman Z-Score : 2.46 (As of Dec. 01, 2024) - GuruFocus.com
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):